## **Synthesis of Pyrrolidine** *C***-Nucleosides via Heck Reaction**

## **Adrian Ha**1**berli and Christian J. Leumann\***

*Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland*

*leumann@ioc.unibe.ch*

**Received December 20, 2000**

## **ORGANIC LETTERS 2001 Vol. 3, No. 3 <sup>489</sup>**-**<sup>492</sup>**



**ABSTRACT**

**A novel method for the synthesis of pyrrolidine** *C***-nucleosides has been developed. The key step of the synthesis is the palladium(0)-mediated coupling of a disubstituted** *N***-protected 2-pyrroline and 5-iodouracil.** *C***-Nucleoside 14 and its** *N***-methyl derivative 15 can easily be converted to the corresponding phosphoramidite building blocks for DNA synthesis.**

In the context of our ongoing research on the synthesis and properties of oligonucleotide analogues, we became interested in an efficient access to pyrrolidine *C*-nucleoside building blocks for DNA synthesis.

Several pyrrolidine *C*-nucleosides with aromatic (hetero) cycles, such as substituted phenyls, imidazoles, or 9-deazaguanine, as aglycons were synthesized as transition state inhibitors for nucleoside hydrolases or nucleoside phosphatases by Schramm and co-workers. The aglycon was introduced via addition of the corresponding aryl-lithium or aryl-Grignard reagents to the imine function of substituted 3,4-dihydro-2H-pyrroles.<sup>1-3</sup> Yokoyama and co-workers synthesized different stereoisomers of pyrrolidine *C*-nucleosides, pyrrolidine 2′-deoxy-*C*-nucleosides, and pyrrolidine 2′,3′ dideoxy-*C*-nucleosides as glycosidase inhibitors. The C-<sup>C</sup>

bond formation was performed by the addition of the lithium or Grignard reagents of the heterocycles to the corresponding substituted  $\gamma$ -lactams or related compounds.<sup>4-7</sup> Abasic pyrrolidine 2′-deoxy-*C*-nucleoside and pyrrolidine 2′-deoxyadenosine with an additional  $CH<sub>2</sub>$ -unit between  $C-1'$  and the base were incorporated into DNA by Verdine and coworkers. These oligomers were tested as inhibitors for glycosidase II and base-excision DNA repair enzymes.<sup>8,9</sup> Starting from 2-deoxy-D-ribose, Kim et al. synthesized *N*-acetyl-pyrrolidine-2′-deoxy-*â*-D-pseudouridine in 19 steps in an overall yield of 3.4% via Staudinger-aza-Wittig cyclization of a 2,4-di-*O*-benzylpyrimidin-5-yl-substituted *γ*-azido ketone.10

Palladium-mediated coupling reactions of furanoid glycals with appropriate aglycon derivatives were successfully employed for the regio- and stereospecific formation of (1) Horenstein, B. A.; Zabinski, R. F.; Schramm, V. L. *Tetrahedron Lett.*

(12) Hsieh, H.-P.; McLaughlin, L. W. *J. Org. Chem.* **1995**, *60*, 5356. (13) Zhang, H.-C.; Brakta, M.; Daves, G. D. *Nucleosides Nucleotides* **1995**, *14*, 105.

(14) Coleman, R. S.; Madaras, M. L. *J. Org. Chem.* **1998**, *63*, 5700.

**<sup>1993</sup>**, *34*, 7213.

<sup>(2)</sup> Furneaux, R. H.; Limberg, G.; Tyler, P. C.; Schramm, V. L. *Tetrahedron* **1997**, *53*, 2915.

<sup>(3)</sup> Evans, G. B.; Furneaux, R. H.; Gainsford, G. J.; Schramm, V. L.; Tyler, P. C. *Tetrahedron* **2000**, *56*, 3053.

<sup>(4)</sup> Yokoyama, M.; Ikeue, T.; Ochiai, Y.; Momotake, A.; Yamaguchi, K.; Togo, H. *J. Chem. Soc., Perkin Trans. 1* **1998**, 2185.

<sup>(5)</sup> Momotake, A.; Mito, J.; Yamaguchi, K.; Togo, H.; Yokoyama, M. *J. Org. Chem.* **1998**, *63*, 7207.

<sup>(6)</sup> Momotake, A.; Togo, H.; Yokoyama, M. *J. Chem. Soc., Perkin Trans. 1* **1999**, 1193.

<sup>(7)</sup> Yokoyama, M.; Ikenogami, T.; Togo, H. *J. Chem. Soc., Perkin Trans. 1* **2000**, 2067.

<sup>(8)</sup> Schärer, O. D.; Ortholand, J.-Y.; Ganesan, A.; Ezaz-Nikpay, K.; Verdine, G. L. *J. Am. Chem. Soc.* **1995**, *117*, 6623.

<sup>(9)</sup> Deng, L.; Schärer, O. D.; Verdine, G. L. *J. Am. Chem. Soc.* 1997, *119*, 7865.

<sup>(10)</sup> Kim, D. C.; Yoo, K. H.; Kim, D. J.; Chung, B. Y.; Park, S. W. *Tetrahedron Lett.* **1999**, *40*, 4825.

<sup>(11)</sup> Farr, R. N.; Outten, R. A.; Cheng, J. C.; Daves, G. D. *Organometallics* **1990**, *9*, 3151.

 $C$ -glycosidic bonds.<sup>11-14</sup> Zhang et al. used Heck chemistry for the synthesis of 2'-deoxypseudouridine<sup>15</sup> (Scheme 1). Less



*<sup>a</sup>* CBz, benzyloxycarbonyl; TBDMS, *tert*-butyldimethylsilyl.

is known about the palladium-catalyzed reactions to form a <sup>C</sup>-C bond between *<sup>N</sup>*-protected enamines and heterocycles.16,17 In this communication we report on the regioand stereospecific synthesis of pyrrolidine-2′-deoxypseudouridine and of its *N*-1-methyl derivative (pyrrolidinepseudothymidine) using Heck chemistry, as well as their elaboration into phosphoramidite building blocks for DNA synthesis. As a key step the palladium-mediated coupling of CBz-protected enamine **5** and 5-iodouracil (**3**) was chosen (Scheme 1).

As starting material the commercially available *trans*-3 hydroxy-L-proline (**6**) was chosen, which already possesses the correct stereochemistry at  $C(2)$  and  $C(3)$ . The amino group was protected as Fmoc carbamate, followed by the selective reduction of the carboxylic acid of **7** with the  $BH<sub>3</sub>·S(CH<sub>3</sub>)<sub>2</sub>$  complex in almost quantitative yield to give diol **8**. <sup>18</sup> In a one-pot reaction, both hydroxy groups were protected as TBDMS ethers, followed by the cleavage of the Fmoc group with piperidine  $(\rightarrow 9)$ . To introduce the enamine functionality, **9** was *N*-chlorinated with NCS followed by the LTMP-mediated elimination of HCl at  $-78$ °C, after a procedure by Schramm and co-workers.2 NMR data of the intermediate 3,4-dihydro-2*H*-pyrrole derivative, which can be isolated by FC, proved that the deprotonation occurred exclusively at the C(5) position. CBz-protected enamine **5** was obtained after the addition of benzyl chloroformate and  $NEt<sub>3</sub>$  to the in situ formed imine at low temperature. Overall yield of **5** from **6** was 52% (Scheme 2).

Our initial experiments on the palladium(0)-catalyzed coupling of enamine **5** with 5-bromo- (**10a**, <sup>19</sup> Scheme 3, Table 1 entries 1 and 2) or 5-iodo-2,4-di-*O*-benzylpyrimidine

- (16) Gurjar, M. K.; Pal, S.; Rao, A. V. R. *Heterocycles* **1997**, *45*, 231.
- (17) Nilsson, K.; Hallberg, A. *J. Org. Chem.* **1990**, *55*, 2464.



 $a$  (a) Fmoc-Cl, dioxane, 5% aq. NaHCO<sub>3</sub> soln, 0 °C  $\rightarrow$  rt, 9 h; (b) BH3'(CH3)2S, THF, reflux, 2 h; (c) TBDMS-Cl, imidazole, THF, rt, 2 h; (d) piperidine, THF, rt, 12 h; (e) NCS (*N*-chlorosuccinimide), hexane, rt, 1 h; (f) LTMP (lithium 2,2,6,6-tetramethylpiperidide), THF,  $-78$  °C, 2 h; (g) benzyl chloroformate, NEt<sub>3</sub>, THF,  $-78$  °C  $\rightarrow$  rt, 8 h.

(**10b**, synthesized from **10a** by Br-Li exchange, followed by the reaction with  $I_2$ , entries  $3-7$ ) were unsuccessful. The coupled product **11** was only obtained in the reaction of **5** and **10b** in low yields of less than 5% using  $Pd(OAc)$ <sub>2</sub> as catalyst with  $PPh_3$  or bppp as ligand and  $NBu_3$  as base and carrying out the reaction in CHCl<sub>3</sub> at 60  $\rm{^{\circ}C}$  for several days (entries  $8$  and  $9$ ).<sup>11</sup> Higher temperatures and longer reaction times led to the decomposition of the starting materials. Iodide **10b** was then replaced by the commercially available, unprotected 5-iodouracil (**3**). The Heck reaction of **5** and **3** using PPh<sub>3</sub>, bppp, or  $P(C_6F_5)$ <sub>3</sub> as ligands led to unreacted



*<sup>a</sup>* Experimental conditions, see Table 1. TBDMS, *tert*-butyldimethylsilyl.

<sup>(15)</sup> Zhang, H.-C.; Daves, G. D. *J. Org. Chem.* **1992**, *57*, 4690.

<sup>(18)</sup> Jordis, U.; Sauter, F.; Siddiqi, S. M.; Küenburg B.; Bhattacharya K. *Synthesis* **1990**, 925.

<sup>(19)</sup> Schinazi, R. F.; Prusoff, W. H. *J. Org. Chem.* **1985**, *50*, 841.



*<sup>a</sup>* Scheme 3, catalyst concentration 10-33 mol %. If no coupling product was observed, the reactions were stopped after 2 days. bppp, 1,3-bis(diphenylphosphino)propane.

starting material or to decomposition at higher temperatures. No product arising from Heck coupling could be isolated (entries  $10-13$ ). Finally, 12 was obtained in a yield of 58% after replacement of the phosphine ligands by the "soft" ligand  $AsPh<sub>3</sub><sup>20</sup>$  and by using DMF as the solvent (entry 14). As expected,  $11-15$  the double bond flipped to the 3,4-position of the pyrrolidine ring. The *R*-configuration of the new stereocenter was proven at a later stage.

Both silyl ethers of **12** were cleaved with TBAF under mild acidic deprotection conditions. At  $-15$  °C the obtained keto group was stereoselectively reduced with NaB-  $(OAc)<sub>3</sub>H<sup>15</sup>$  Diol 4 was separated by FC from a minor stereoisomer (<5%), which was not further analyzed. The corresponding *N*-1-Me compound **13** was obtained in 77%

yield after reaction of the tetrasilyl derivative of **4**, which was prepared in situ, with CH<sub>3</sub>I for 70 h.<sup>21</sup> Pd-catalyzed hydrogenation of the CBz group of **4** and **13** was achieved at a  $H_2$  pressure of 1 bar. For determination of the relative configuration, amine **14** was converted into the *N*-acetyl compound **16**. The NMR data of **16** were identical with those reported for the same compound in the literature<sup>10</sup> and proved the expected (2*R*,4*S*,5*R*)-configuration (independent confirmation by NOE experiments). For the remaining part of the synthesis, **14** and **15** were *N*-protected with the Fmoc group that was shown earlier to be compatible with standard oligonucleotide synthesis.8 The phosphoramidite building blocks **19** and **20** were obtained by dimethoxy-tritylation of the primary alcohol of **17** and **18**, respectively, followed by



*a* (a) AcOH, TBAF, THF,  $-15 \degree C \rightarrow \text{rt}$ , 37 h; (b) NaB(OAc)<sub>3</sub>H, AcOH, CH<sub>3</sub>CN,  $-15 \degree C \rightarrow \text{rt}$ , 20 min; (c) BSA, CH<sub>3</sub>I, CH<sub>2</sub>Cl<sub>2</sub>, rt, 70 h; (d) H<sub>2</sub>, Pd/C, MeOH, rt, 4 h; (e) Ac<sub>2</sub>O, MeOH, H<sub>2</sub>O, 0 °C  $\rightarrow$  rt, 2.5 h; (f) Fmoc-OSu, THF, dioxane, 5% aq. NaHCO<sub>3</sub> soln, rt, 3 h; (g) DMT-Cl, pyridine, rt, 2 h; (h) ( $iPr_2N$ )(NCCH<sub>2</sub>CH<sub>2</sub>O)PCl,  $iPr_2NEt$ , THF, rt, 2 h.

reaction with 2-cyanoethyl *N*,*N*-diisopropylchlorophosphoramidite. The amidites **19** and **20** can be directly used for standard cyanoethyl phosphoramidite oligonucleotide synthesis. The total yields of **19** and **20** from **6** were 14% and 6%, respectively (Scheme 4).

In conclusion, an efficient method for the syntheses of the pyrrolidine-2′-deoxypseudouridine phosphoramidite building block **19** and its *N*-1-methyl derivative **20** (pyrrolidinepseudothymidin) was developed. It was shown that Hecktype reactions can be employed to build up pyrrolidine *C*-nucleosides from the corresponding *N*-protected enamines and functionalized heterocycles. However, the reaction conditions, especially the tuning of the electronic properties

of the ligand, are critical for the success of the Pd-catalyzed coupling. AsPh<sub>3</sub> as a "soft" ligand of monodentate donicity proved to be appropriate.

The incorporation of the new phosphoramidites into oligonucleotides and the evaluation of their biophysical and biological properties are in progress.

**Acknowledgment.** This work was supported by a research grant from the Swiss National Science Foundation and a Ph.D. grant from Novartis.

**Supporting Information Available:** Experimental procedure for the synthesis of all compounds and their spectroscopic characterization. This material is available free of charge via the Internet at http://pubs.acs.org.

OL007029S

<sup>(20)</sup> Kojima, A.; Honzawa, S.; Boden, C. D. J.; Shibasaki, M. *Terahedron Lett.* **1997**, *38*, 3455.

<sup>(21)</sup> Bhattacharya, B. K.; Devivar, R. V.; Revankar, G. R. *Nucleosides Nucleotides* **1995**, *14*, 1269.